Article Details
Retrieved on: 2025-04-02 17:04:01
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Amgen's 2024 achievements in public health by advancing orphan drugs and monoclonal antibodies. Key products, such as Repatha and Blincyto, emphasize their role in treating various health conditions like obesity and rare diseases. Pharmaceutical innovation, research, and the manufacturing expansion underscore their further commitment to addressing public health challenges.
Article found on: www.amgen.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here